SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 8,699.00 |
| Enterprise Value ($M) | 7,491.17 |
| Book Value ($M) | 5,580.04 |
| Book Value / Share | 7.67 |
| Price / Book | 1.56 |
| NCAV ($M) | 5,175.13 |
| NCAV / Share | 7.11 |
| Price / NCAV | 1.68 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.81 |
| Return on Assets (ROA) | 2.33 |
| Return on Equity (ROE) | 3.63 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 10.37 |
| Current Ratio | 10.43 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 5,801.12 |
| Assets | 6,206.03 |
| Liabilities | 625.99 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 124.80 |
| Operating Income | -1,079.94 |
| Net Income | 4,348.93 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -765.27 |
| Cash from Investing | 5,203.62 |
| Cash from Financing | 419.36 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Viking Global Investors Lp | 7.30 | -22.01 | |
| 13G | Fmr Llc | 6.64 | ||
| 13G/A | Vanguard Group Inc | 5.63 | 0.00 | |
| 13G | BlackRock, Inc. | 5.70 | 0.00 | |
| 13G/A | Sumitomo Chemical Co., Ltd. | 0.00 | -100.00 | |
| 13G/A | QVT Financial LP | 8.28 | -40.72 | |
| 13G/A | Dexcel Pharma Technologies Ltd. | 12.78 | 0.00 | |
| 13G/A | Ramaswamy Vivek | 9.75 | 0.00 | |
| 13G/A | Sb Investment Advisers (uk) Ltd | 9.10 | -23.15 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 893,679 | 4,745,790 | 18.83 | |
| 1,825,810 | 10,629,105 | 17.18 | |
| 864,664 | 4,282,910 | 20.19 | |
| 1,549,086 | 5,403,954 | 28.67 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| RIGL – Rigel Pharmaceuticals, Inc. | RLMD – Relmada Therapeutics, Inc. |
| RLYB – Rallybio Corporation | RPRX – Royalty Pharma plc |
| RPTX – Repare Therapeutics Inc. |
Financial data and stock pages provided by
Fintel.io